Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Randomized, Open-label, Multicenter Efficacy and Safety Study of Standard Dose of Radium-223 Dichloride vs. Standard Doses of Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Bone Dominant Metastatic Castration Resistant Prostate Cancer (mCRPC) Progressing on/After One Line of ARPI

NCT04597125 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT04597125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04597125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Randomized, Open-label, Multicenter Efficacy and Safety Study of Standard Dose of Radium-223 Dichloride vs. Standard Doses of Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Bone Dominant Metastatic Castration Resistant Prostate Cancer (mCRPC) Progressing on/After One Line of ARPI
Lead sponsor
Bayer
Phase
Phase 4
Overall status
Active, not recruiting
Start date
November 9, 2020
Completion date
October 12, 2026
Enrollment
654 (actual)
Sites
118

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castrate resistant prostate cancer (mcrpc)